Shopping Cart
- Remove All
Your shopping cart is currently empty
JGB1741 (ILS-JGB-1741) is a potent and selective inhibitor of SIRT1 with an IC50 of 15 μM. It modulates the Bax/Bcl2 ratio, cytochrome c release, and PARP cleavage, and increases acetylated p53 levels, leading to p53-mediated apoptosis. JGB1741 can be used in breast cancer studies.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $54 | In Stock | |
| 5 mg | $178 | In Stock | |
| 10 mg | $297 | In Stock | |
| 25 mg | $523 | In Stock | |
| 50 mg | $759 | In Stock | |
| 100 mg | $1,060 | In Stock |
| Description | JGB1741 (ILS-JGB-1741) is a potent and selective inhibitor of SIRT1 with an IC50 of 15 μM. It modulates the Bax/Bcl2 ratio, cytochrome c release, and PARP cleavage, and increases acetylated p53 levels, leading to p53-mediated apoptosis. JGB1741 can be used in breast cancer studies. |
| Targets&IC50 | SIRT3:>100 μM, SIRT1:∼15 μM, SIRT2:>100 μM |
| In vitro | JGB1741 (1-10000 nM) inhibits the cell proliferation of K562, HepG2 and MDA-MB 231 cell lines. JGB1741 (0.01-1 μM) induces apoptosis of MDA-MB 231 and shows a cell cycle arrest at G1 phase with more cells entering into sub G0/G1 phase. JGB1741 (0.01-1 μM) increases the global acetylation of H3K9, acetylated p53K382 levels and p53 expression[1]. |
| Synonyms | ILS-JGB-1741 |
| Molecular Weight | 440.56 |
| Formula | C27H24N2O2S |
| Cas No. | 1256375-38-8 |
| Smiles | Oc1ccc2ccccc2c1\C=N\c1sc2CCCCc2c1C(=O)NCc1ccccc1 |
| Relative Density. | 1.28 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 4.41 mg/mL (10 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.